DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia

Drug resistance is a critical obstacle to effective treatment in patients with chronic myeloid leukemia. To understand the underlying resistance mechanisms in response to imatinib mesylate (IMA) and adriamycin (ADR), the parental K562 cells were treated with low doses of IMA or ADR for 2 months to g...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Sun, Yaoting, Ge, Weigang, Zhang, Fangfei, Gan, Lin, Zhu, Yi, Guo, Tiannan, Liu, Kexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800142/
https://www.ncbi.nlm.nih.gov/pubmed/34922009
http://dx.doi.org/10.1016/j.mcpro.2021.100187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800142/
https://www.ncbi.nlm.nih.gov/pubmed/34922009
http://dx.doi.org/10.1016/j.mcpro.2021.100187

Ejemplares similares